Immunotherapy reduces vascular amyloid-beta in PDAPP mice

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Alzheimer's disease (AD) involves amyloid-beta (Abeta) plaques and cerebral amyloid angiopathy (CAA).
• Passive immunization strategies for AD may impact vascular Abeta (VAbeta) and microhemorrhage.
• The effects of antibody specificity and dose on VAbeta and microhemorrhage are not well understood.

Purpose of the Study:

• To investigate the impact of chronic passive immunization with anti-Abeta antibodies on VAbeta and microhemorrhage in PDAPP mice.
• To compare the efficacy of antibodies targeting different Abeta epitopes (3D6 vs. 266).
• To determine the dose-response relationship of the 3D6 antibody on VAbeta and microhemorrhage.

Main Methods:

• Utilized PDAPP transgenic mice for Alzheimer's disease modeling.
• Administered chronic passive immunization with anti-Abeta antibodies (3D6 and 266).
• Assessed VAbeta and microhemorrhage using immunohistochemistry and hemosiderin detection.

Main Results:

• The 3D6 antibody (targeting Abeta 1-5) dose-dependently reduced or prevented VAbeta, while the 266 antibody (targeting Abeta 16-23) had no effect.
• Essentially complete VAbeta absence was observed at the highest 3D6 dose; altered morphology suggesting clearance was seen at lower doses.
• Microhemorrhage incidence increased in the high-dose 3D6 group, localized to perivascular sites with Abeta deposits.

Conclusions:

• Passive immunization can reduce VAbeta levels in a mouse model.
• Antibody dose modulation is critical for mitigating microhemorrhage risk while achieving VAbeta reduction.
• Abeta immunotherapy may offer a potential strategy to slow or halt CAA development in Alzheimer's disease.